Art

J-GLOBAL ID：201002209318936667   Reference number：10A1001979

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

BRAF変異を有する黒色腫でのRAF阻害剤の臨床的有効性には広範な標的の遮断が必要である

Author (40)： BOLLAG Gideon (Plexxikon Inc., California, USA) ,  HIRTH Peter (Plexxikon Inc., California, USA) ,  TSAI James (Plexxikon Inc., California, USA) ,  ZHANG Jiazhong (Plexxikon Inc., California, USA) ,  IBRAHIM Prabha N. (Plexxikon Inc., California, USA) ,  CHO Hanna (Plexxikon Inc., California, USA) ,  SPEVAK Wayne (Plexxikon Inc., California, USA) ,  ZHANG Chao (Plexxikon Inc., California, USA) ,  ZHANG Ying (Plexxikon Inc., California, USA) ,  HABETS Gaston (Plexxikon Inc., California, USA) ,  BURTON Elizabeth A. (Plexxikon Inc., California, USA) ,  WONG Bernice (Plexxikon Inc., California, USA) ,  TSANG Garson (Plexxikon Inc., California, USA) ,  WEST Brian L. (Plexxikon Inc., California, USA) ,  POWELL Ben (Plexxikon Inc., California, USA) ,  SHELLOOE Rafe (Plexxikon Inc., California, USA) ,  MARIMUTHU Adhirai (Plexxikon Inc., California, USA) ,  NGUYEN Hoa (Plexxikon Inc., California, USA) ,  ZHANG Kam Y. J. (Plexxikon Inc., California, USA) ,  ARTIS Dean R. (Plexxikon Inc., California, USA) ,  LIN Paul S. (Plexxikon Inc., California, USA) ,  NOLOP Keith (Plexxikon Inc., California, USA) ,  SCHLESSINGER Joseph (Yale Univ., Connecticut, USA) ,  SU Fei (Roche Pharmaceuticals, New Jersey, USA) ,  HIGGINS Brian (Roche Pharmaceuticals, New Jersey, USA) ,  IYER Raman (Roche Pharmaceuticals, New Jersey, USA) ,  KOEHLER Astrid (Roche Pharmaceuticals, New Jersey, USA) ,  STUMM Michael (Roche Pharmaceuticals, New Jersey, USA) ,  LEE Richard J. (Roche Pharmaceuticals, New Jersey, USA) ,  GRIPPO Joseph (Roche Pharmaceuticals, New Jersey, USA) ,  D'ANDREA Kurt (Univ. Pennsylvania, Pennsylvania, USA) ,  FLAHERTY Keith T. (Univ. Pennsylvania, Pennsylvania, USA) ,  XU Xiaowei (Univ. Pennsylvania, Pennsylvania, USA) ,  NATHANSON Katherine L. (Univ. Pennsylvania, Pennsylvania, USA) ,  PUZANOV Igor (Vanderbilt Univ., Tennessee, USA) ,  SOSMAN Jeffrey A. (Vanderbilt Univ., Tennessee, USA) ,  KIM Kevin B. (Univ. Texas M. D. Anderson Cancer Center, Texas, USA) ,  RIBAS Antoni (Univ. California, Los Angeles, California, USA) ,  MCARTHUR Grant A. (Peter MacCallum Cancer Centre, Melbourne, AUS) ,  CHAPMAN Paul B. (Memorial Sloan Kettering Cancer Center, New York, USA)
Material： Nature (London)  (Nature (Lond))
Volume： 467  Issue： 7315  Page： 596-599  Publication year： Sep. 30, 2010 
JST Material Number： D0193B  ISSN： 0028-0836  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： *MAP kinase kinase kinase ,  oncoprotein ,  *enzyme inhibitor ,  antitumor drug ,  human ,  Melanoma ,  phase 1 study ,  oral administration ,  Mutation ,  antitumor action ,  *Protein Kinase Inhibitors ,  Signal Transduction ,  *Proto-Oncogene Proteins B-raf ,  molecular targeting drug
Semi thesaurus term： cellular signal transduction ,  *B-Raf ,  phase I study

JST classification (1)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (1)： Vemurafenib

Terms in the title (8)： BRAF ,  変異 ,  黒色腫 ,  Raf ,  阻害剤 ,  臨床的有効性 ,  標的 ,  遮断